Study Design for Descriptive Dose Comparison Sub-Study
Daily Sotorasib 240 mg vs 960 mg

CodeBreaK 100

Phase II, Multicenter, Open-Label Study – Dose Comparison



*Objective response will be assessed per RECIST 1.1 by blinded independent central review. CR or PR requires confirmatory CT or MRI repeat assessment at least 4 weeks after the initial detection of response.
†Subjects with a confirmed progression will be allowed to continue treatment at their assigned dose if all criteria is met; cross-over to the alternate dosing arm is not permitted.
‡30 (+7) days after end of treatment for safety follow-up; every 12 weeks for long-term follow-up.

AE, adverse event; **ALK,** anaplastic lymphoma kinase; **BICR,** blinded independent central review; **CNS**, central nervous system; **CR,** complete response; **DCR,** disease control rate; **DoR,** duration of response; **ECOG PS,** Eastern Cooperative Oncology Group Performance Status; **EGFR,** epidermal growth factor receptor; **EOI,** event of interest; **GFR,** glomerular filtration rate; **KRAS,** Kirsten rat sarcoma viral oncogene homolog; **NSCLC,** non-small cell lung cancer; **ORR,** objective response rate; **OS,** overall survival; **PD,** disease progression; **PFS,** progression-free survival; **PK,** pharmacokinetic; **PR,** partial response; **QD,** once daily; **RECIST,** response evaluation criteria in solid tumors; **TEAE,** treatment-emergent adverse event.